Journal
HAEMATOLOGICA
Volume 102, Issue 4, Pages 614-625Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2016.150250
Keywords
-
Categories
Funding
- Japan Society for the Promotion of Science [15K19563]
- Friends of Leukemia Research Fund
- National Institutes of Health [CA18953, CA18029]
- Grants-in-Aid for Scientific Research [15K19563] Funding Source: KAKEN
Ask authors/readers for more resources
Hematopoietic cell transplantation is a curative treatment for a variety of hematologic diseases. Advances in transplantation technology have reduced early transplant-related mortality and expanded application of transplantation to older patients and to a wider variety of diseases. Management of late effects after transplantation is increasingly important for a growing number of long-term survivors that is estimated to be half a million worldwide. Many studies have shown that transplant survivors suffer from significant late effects that adversely affect morbidity, mortality, working status and quality of life. Late effects include diseases of the cardiovascular, pulmonary, and endocrine systems, dysfunction of the thyroid gland, gonads, liver and kidneys, infertility, iron overload, bone diseases, infection, solid cancer, and neuropsychological effects. The leading causes of late mortality include recurrent malignancy, lung diseases, infection, secondary cancers and chronic graft-versus-host disease. The aim of this review is to facilitate better care of adult transplant survivors by summarizing accumulated evidence, new insights, and practical information about individual late effects. Further research is needed to understand the biology of late effects allowing better prevention and treatment strategies to be developed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available